Bicara Therapeutics Inc (NASDAQ:BCAX) price on Friday, June 13, fall -6.31% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $10.84.
A look at the stock’s price movement, the close in the last trading session was $11.57. Turning to its 52-week performance, $28.09 and $7.80 were the 52-week high and 52-week low respectively. Overall, BCAX moved -20.88% over the past month.
Bicara Therapeutics Inc’s market cap currently stands at around $591.17 million, with investors looking forward to this quarter’s earnings report slated for in July.
BCAX’s current price about -7.87% and -12.60% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 44.08, while 7-day volatility ratio is 7.25% and 13.03% in the 30-day chart. Further, Bicara Therapeutics Inc (BCAX) has a beta value of 0, and an average true range (ATR) of 1.32. Analysts have given the company’s stock an average 52-week price target of $28, forecast between a low of $8 and high of $48. Looking at the price targets, the low is 26.2% off current price level while to achieve the yearly target high, price needs to move -342.8%. Nonetheless, investors will most likely welcome a -158.3% jump to $28 which is the analysts’ median price.
If we refocus on Bicara Therapeutics Inc (NASDAQ:BCAX), historical trading data shows that trading volumes averaged 820.87K over the past 3 months. The company’s latest data on shares outstanding shows there are 54.53 million shares.
The 39.92% of Bicara Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 62.30% of the company’s shares. Current price change has pushed the stock -37.77% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BCAX stock continues to rise going into the next quarter.
